GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Centogene NV (STU:39K) » Definitions » Total Liabilities

Centogene NV (STU:39K) Total Liabilities : €102.44 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Centogene NV Total Liabilities?

Centogene NV's Total Liabilities for the quarter that ended in Dec. 2023 was €102.44 Mil.

Centogene NV's quarterly Total Liabilities increased from Dec. 2022 (€85.40 Mil) to Jun. 2023 (€87.11 Mil) and increased from Jun. 2023 (€87.11 Mil) to Dec. 2023 (€102.44 Mil).

Centogene NV's annual Total Liabilities increased from Dec. 2021 (€63.88 Mil) to Dec. 2022 (€85.40 Mil) and increased from Dec. 2022 (€85.40 Mil) to Dec. 2023 (€102.44 Mil).


Centogene NV Total Liabilities Historical Data

The historical data trend for Centogene NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centogene NV Total Liabilities Chart

Centogene NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 58.59 84.99 63.88 85.40 102.44

Centogene NV Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.30 69.11 85.40 87.11 102.44

Centogene NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Centogene NV's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=43.366+(52.279+0.68399999999999
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+6.108+0)
=102.44

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=77.155--25.282
=102.44

Centogene NV's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=43.366+(52.279+0.68399999999999
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+6.108+0)
=102.44

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=77.155--25.282
=102.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Centogene NV Total Liabilities Related Terms

Thank you for viewing the detailed overview of Centogene NV's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Centogene NV (STU:39K) Business Description

Traded in Other Exchanges
Address
Am Strande 7, Rostock, MV, DEU, 18055
Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company operates in three segments: pharmaceutical, diagnostics, and COVID-19. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.

Centogene NV (STU:39K) Headlines

No Headlines